Prompt Approval of Safe Generic Drugs Act

1. 01

   How might allowing generic drugs to have different safety labels than brand-name drugs affect patient safety and medication error rates?

2. 02

   Which stakeholders—generic manufacturers, brand-name companies, or patients—would benefit most from this labeling flexibility change?

3. 03

   What evidence exists that current FDA approval processes for generic drugs delay patient access to affordable medications?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.